| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Collins Helen Louise is a Chief Medical Officer at ELVN. Recent filings cover 0 purchases and 27 sales. Those positions are worth an estimated $962K at current prices.
Our model assigns Collins Helen Louise a middling insider score of 64/100, based on 5 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +28.4%.
Collins Helen Louise's largest disclosed position is in ELVN as Chief Medical Officer, worth about $962K. The recent filings there lean toward selling, a net 185,816 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $38.47 | $192,342.00 | -16.7% | - | - | |
| Sep 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $50.35 | $251,753.87 | -16.7% | - | - | |
| Aug 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $58.59 | $292,930.78 | -16.7% | - | - | |
| Jul 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $52.67 | $263,373.38 | -16.7% | -26.1% | - | |
| Jun 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $43.80 | $219,016.84 | -16.7% | +18.9% | - | |
| May 18, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $39.79 | $198,971.39 | -16.7% | +50.2% | - | |
| Apr 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $47.67 | $238,352.42 | -16.7% | +5.7% | - | |
| Mar 25, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 40,000 | $35.10 | $1,404,024.00 | -61.5% | +36.8% | - | |
| Mar 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $27.76 | $138,800.00 | -16.7% | +52.4% | - | |
| Mar 10, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 40,000 | $30.07 | $1,202,637.98 | -61.5% | +11.2% | - |